Adverse neurological events associated with bispecific T cell engagers in oncology: a real-world study
Frontiers in Pharmacology · 21.05.2026 · 17
DOI: 10.3389/fphar.2026.1819689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.05.2026. Verfasst von Qianqian Cui und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First College of Clinical Medical Science, China Three Gorges University and Yichang Central People's Hospital, Yichang, …. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
With the increasing use of bispecific T cell engagers (BiTEs) in anti-tumor immunotherapy, the associated adverse reactions pose significant challenges to clinical application. Nervous system toxicity (NST) is one of the notable adverse events associated with this class of drugs. This study aims to provide a comprehensive analysis of BiTE-induced nervous system adverse events. Improving the diagnosis and monitoring of these adverse events is crucial for the early identification and treatment of NSTs.
Methods
We utilized the FAERS database to analyze NSTs associated with BiTEs reported between January 2004 and September 2025. Positive safety signals of the drugs were assessed using four commonly applied disproportionality analysis methods. In addition, the time to onset of drug-induced adverse reactions was evaluated.
Results
A total of 15,558 patients who developed NSTs during BiTE therapy were included in this study. The average age at NST onset was 51.12 ± 24.44 years. The incidence was 21.19% higher in men than in women (6,139 men vs. 5,065 women), with the United States reporting the highest proportion of cases (50.68%). Among the BiTEs analyzed, blinatumomab accounted for the highest number of reported cases (49.63%). The NSTs observed include immune effector cell-associated neurotoxicity syndrome and other forms of neurotoxicity. Tremor, seizures, and nervous system disorders were reported more frequently with blinatumomab. In the comparative analysis of drug induction time, glofitamab exhibited the longest induction time [82.00 days (range, 1∼1190)], whereas tarlatamab showed the shortest time [16.70 days (range, 1∼141)].
Conclusion
BiTEs have the potential to induce significant adverse events within the central nervous system and may exacerbate pre-existing conditions. Given the increasing utilization of BiTEs, it is essential to integrate resources such as the FAERS database to effectively monitor adverse reactions associated with these novel therapeutic agents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, The First College of Clinical Medical Science, China Three Gorges University and Yichang Central People's Hospital, Yichang, China.
- Department of Neurosurgery, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zitieren
APA
Cui, Q., Gao, S., Liu, H., Zhou, H., & Li, Y. (2026). Adverse neurological events associated with bispecific T cell engagers in oncology: a real-world study. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1819689
Vancouver
Cui Q, Gao S, Liu H, Zhou H, Li Y. Adverse neurological events associated with bispecific T cell engagers in oncology: a real-world study. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1819689
BibTeX
@article{Cui2026,
author = {Cui, Qianqian and Gao, Shuangqi and Liu, Hongyu and Zhou, Haiyun and Li, Yunxiao},
title = {Adverse neurological events associated with bispecific T cell engagers in oncology: a real-world study},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1819689}
}
EUVIMED